Neonatal HBV Vaccination Reduces Liver Cancer Risk

A follow-up study spanning 30 years shows that vaccinating babies against HBV reduces their risk of liver disease in adulthood.

AsianScientist (Jan. 7, 2015) – According to a study published in PLOS Medicine, neonatal hepatitis B (HBV) vaccination can reduce the risk of liver cancer and other liver diseases in young adults in China.

The team of researchers from the Cancer Institute & Hospital at the Chinese Academy of Medical Sciences, Qidong Liver Cancer Institute and Yale School of Public Health and School of Medicine, report long-term outcomes from the Qidong Hepatitis B intervention Study (QHBIS), a randomized controlled trial of neonatal HBV vaccination.

The study was conducted between 1983 and 1990 in Qidong County, a rural area in China with a high incidence of HBV-related primary liver cancer (PLC) and other liver diseases. In this study, 41 rural towns (including a total of 77,658 newborns over the study period) were randomized to the intervention (HBV vaccination for all newborns) or control (no vaccination) groups, with two-thirds of the control group participants receiving a catch-up vaccination at age 10-14 years.

By collecting data on new cases of liver diseases over 30 years from a population-based tumor registry, the researchers estimated that the protective efficacy of vaccination was 84 percent for primary liver cancer, 70 percent for death from liver diseases and 69 percent for the incidence of infant fulminant hepatitis.

Based on survey data collected in 1996-2000 and 2008-2012 on HBsAg seroprevalence, an indicator of current hepatitis B virus (HBV) infection, they conclude that the efficacy of the catch-up vaccination on HBsAg seroprevalence in early adulthood was weak compared to neonatal vaccination (21 percent versus 72 percent).

While these findings support the importance of neonatal HBV vaccination, the small number of cases of primary liver cancer and other liver diseases observed during the 30-year follow up, the length of follow-up and the availability of incomplete data on seroprevalence all limit the accuracy of these findings.

The authors say: “Neonatal HBV vaccination significantly decreased HBsAg seroprevalence in childhood through young adulthood and subsequently reduced the risk of PLC and other liver diseases in young adults.” They continue: “Our results also suggest that an adolescence booster should be considered in people who were born to HBsAg-positive mothers and completed HBV neonatal vaccination series.”

The article can be found at: Qu et al. (2014) Efficacy of Neonatal HBV Vaccination on Liver Cancer and Other Liver Diseases over 30-Year Follow-up of the Qidong Hepatitis B Intervention Study: A Cluster Randomized Controlled Trial.

——

Source: PLOS; Photo: Shutterstock.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

Asian Scientist Magazine is an award-winning science and technology magazine that highlights R&D news stories from Asia to a global audience. The magazine is published by Singapore-headquartered Wildtype Media Group.

Related Stories from Asian Scientist